🇺🇸 FDA
Patent

US 8623383

Recombinant antigens for diagnosis and prevention of spotted fever rickettsiae

granted A61KA61K39/00

Quick answer

US patent 8623383 (Recombinant antigens for diagnosis and prevention of spotted fever rickettsiae) held by United States of America as represented by the Secretary of the Air Force expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States of America as represented by the Secretary of the Air Force
Grant date
Tue Jan 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K39/00